"Under the terms of the JV proposal, MTSL will hav
Post# of 30028
(Total Views: 348)
Posted On: 10/21/2018 3:36:55 PM
"Under the terms of the JV proposal, MTSL will have the exclusive option (the Option) to acquire a total of 90% of Cutanogen Corporation oustanding shares in exchange for 50% of the then outstanding common shares of MTSL (the Merger) upon Cutanogen entering into an expanded license agreement with the Shriners Hospitals and the University of Cincinnati that will add additional intellectual property related to the addition of hair follicles and sweat glands to the base ESS technology."
https://www.otcmarkets.com/stock/AMBS/news/Jo...?id=207613
Cutanogen Appoints Richard Kagan, MD as Chief Medical Advisor
APRIL 23, 2018
Emeritus Chief of Staff of Shriners Burns Hospital - Cincinnati to lead Pivotal Trial design
Prior to joining Cutanogen, Dr. Kagan had retired from a career as a tenured Professor of Surgery at the University of Cincinnati College of Medicine as well as the Chief of Staff at the Shriners Burn Hospital in Cincinnati, Ohio where the ESS technology was clinically developed. Dr. Kagan is a past President of the American Burn Association, and previously served as a member of the American College of Surgeons Committee on Trauma and the President of the American Association of Tissue Banks. Dr. Kagan serves on the Editorial Board of the Journal of Burn Care & Research and has been an invited reviewer for the Journal of Trauma and Acute Care Surgery, the Annals of Surgery, the Annals of Plastic Surgery, Burns and Surgery. Dr. Kagan has authored over 130 peer-reviewed publications, 20 book chapters in medical textbooks, and has been an investigator or co-investigator of over 35 research & development grants.
https://www.amarantus.com/news/press-releases...ef-medical
Aloha
https://www.otcmarkets.com/stock/AMBS/news/Jo...?id=207613
Cutanogen Appoints Richard Kagan, MD as Chief Medical Advisor
APRIL 23, 2018
Emeritus Chief of Staff of Shriners Burns Hospital - Cincinnati to lead Pivotal Trial design
Prior to joining Cutanogen, Dr. Kagan had retired from a career as a tenured Professor of Surgery at the University of Cincinnati College of Medicine as well as the Chief of Staff at the Shriners Burn Hospital in Cincinnati, Ohio where the ESS technology was clinically developed. Dr. Kagan is a past President of the American Burn Association, and previously served as a member of the American College of Surgeons Committee on Trauma and the President of the American Association of Tissue Banks. Dr. Kagan serves on the Editorial Board of the Journal of Burn Care & Research and has been an invited reviewer for the Journal of Trauma and Acute Care Surgery, the Annals of Surgery, the Annals of Plastic Surgery, Burns and Surgery. Dr. Kagan has authored over 130 peer-reviewed publications, 20 book chapters in medical textbooks, and has been an investigator or co-investigator of over 35 research & development grants.
https://www.amarantus.com/news/press-releases...ef-medical
Aloha
(4)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼